IMF Videos Search Content For Healthcare Professional (182) Healthcare Provider (182) Series - Any - About the IMF (2) ASCO/EHA (163) ASH (230) Ask Dr. Durie (247) Black Swan Research Initiative (7) Community Workshops (33) Emerging Therapies (20) Facebook Live (21) Health Equity (16) IMF History (4) IMWG (13) Inspirational (16) Living Well with Myeloma (34) Myeloma in a Minute (19) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (27) Q&A (19) Recent News and Developments (4) Treatments (4) Trending Searches in Myeloma (1) Topics Clinical Trials (136) Financial Considerations (1) Frontline Therapy (34) Health Equity (10) Inspirational Stories (1) Lab & Imaging Tests (26) Lifestyle (4) Mental & Emotional Health (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (80) Research Updates (151) Symptom Management (8) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (31) High-Risk Myeloma (29) High-risk Smoldering Myeloma (13) Late Relapse (4–6 Lines of Therapy) (63) MGUS (18) Newly Diagnosed (Pre-Treatment or First Treatment) (52) Smoldering Myeloma (22) Types of Therapy Immunomodulatory drugs (IMiDs) (57) Immunotherapies (CAR T; BiTE, etc.) (60) Monoclonal antibodies (49) Proteasome inhibitors (50) Stem cell transplant (38) Steroids (21) Supportive Care (17) Year Published 2026 (7) 2025 (24) 2024 (23) 2023 (21) 2022 (34) 2021 (27) 2020 (18) 2019 (32) 2018 (30) 2017 (5) 2016 (3) 2015 (6) Trusted Voices Dr. María-Victoria Mateos (8) Dr. Saad Usmani (4) Dr. Shaji Kumar (4) Dr. Brian GM Durie (3) Dr. Joseph Mikhael (3) Dr. Sagar Lonial (1) Dr. Sigurður Kristinsson (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Impact of Daratumumab Monotherapy on Bone Parameters in Relapsed Refractory Multiple Myeloma Pts December 14, 2019 ASH Negatività minima della malattia residua come fattori predittivi di recidiva precoce nei pazienti affetti da mieloma multiplo idoneo al trapianto December 14, 2019 ASH Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients December 14, 2019 ASH Εδραίωση με Carfilzomib, Lenalidomide και Dexamethasone (KRd) December 14, 2019 ASH Carfilzomib, Lenalidomide and Dex (KRd) After ASCT Results in High Rates of MRD Negativity December 14, 2019 ASH A Combined Analysis of the STORM and Mammoth Studies December 13, 2019 ASH Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with RRMM December 13, 2019 ASH Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial December 13, 2019 ASH La espectrometría de masa Qip en pts con MM de alto riesgo latente incluidos en el ensayo GEM-CESAR December 13, 2019 ASH 4-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone December 13, 2019 ASH Dara-KRd Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, MRD-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma December 12, 2019 ASH Depth of Response to Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Improves over Time in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma: Griffin Study Update December 12, 2019 ASH Load More
